Advertisement

Topics

Rituximab pharmacokinetics not associated with response in ANCA-associated vasculitis

09:55 EDT 19 Jun 2017 | Healio

MADRID — No association was observed between pharmacokinetic levels of rituximab and clinical response in patients with ANCA-associated vasculitis, according to findings presented at the EULAR Annual Congress.Divi Cornec, MD, of the Mayo Clinic in Rochester, Minn., and of the Department of Rheumatology at CHRU Brest in France, said clinical response to rituximab (Rituxan, Genentech) has been historically heterogeneous in ANCA-associated vasculitis (AAV). Although around 75% of patients reach remission after infusion, Cornec noted that 30% of those complete responders relapse the following year.

Original Article: Rituximab pharmacokinetics not associated with response in ANCA-associated vasculitis

NEXT ARTICLE

More From BioPortfolio on "Rituximab pharmacokinetics not associated with response in ANCA-associated vasculitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...